Simulated clinical trials

Fig 2

Antiviral therapy achieves almost complete effectiveness for many viral infections such as HIV and hepatitis C.  Yet, for other viral infections such as CMV and HSV-2, there is only partial treatment efficacy and substantial variability in therapeutic response among infected persons. We developed models to explain the phenomenon of breakthrough viral shedding while on antiviral agents.  Our models are highly flexible to simulate various viral infections, and are also highly predictive. This allows us to accurately simulate clinical trials with the goal of dose optimization.